Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,066,349 papers from all fields of science
Search
Sign In
Create Free Account
Overall Survival
A measure of the time until death from any cause.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. Antonia
,
A. Villegas
,
+30 authors
M. Özgüroğlu
New England Journal of Medicine
2018
Corpus ID: 52911032
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as…
Expand
Highly Cited
2017
Highly Cited
2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Wolchok
,
V. Chiarion-Sileni
,
+30 authors
J. Larkin
New England Journal of Medicine
2017
Corpus ID: 205102506
BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate…
Expand
Highly Cited
2016
Highly Cited
2016
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst
,
P. Baas
,
+16 authors
E. Garon
The Lancet
2016
Corpus ID: 23045890
Highly Cited
2015
Highly Cited
2015
Improved overall survival in melanoma with combined dabrafenib and trametinib.
C. Robert
,
B. Karaszewska
,
+24 authors
D. Schadendorf
New England Journal of Medicine
2015
Corpus ID: 205097422
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously…
Expand
Review
2011
Review
2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman
,
A. Hauschild
,
+25 authors
G. McArthur
New England Journal of Medicine
2011
Corpus ID: 4140915
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more…
Expand
Highly Cited
2010
Highly Cited
2010
Improved survival with ipilimumab in patients with metastatic melanoma.
F. Hodi
,
S. O’Day
,
+26 authors
W. Urba
New England Journal of Medicine
2010
Corpus ID: 18582698
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3…
Expand
Highly Cited
2010
Highly Cited
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised…
Y. Bang
,
E. Cutsem
,
+13 authors
Yoon-Koo Kang
The Lancet
2010
Corpus ID: 8825706
Highly Cited
2009
Highly Cited
2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
R. Motzer
,
Thomas E. Hutson
,
+16 authors
R. Figlin
Journal of Clinical Oncology
2009
Corpus ID: 7675933
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free…
Expand
Highly Cited
2009
Highly Cited
2009
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
A. Cheng
,
Yoon-Koo Kang
,
+18 authors
Z. Guan
The Lancet Oncology
2009
Corpus ID: 35610395
Highly Cited
2008
Highly Cited
2008
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Steven J. Cohen
,
C. Punt
,
+11 authors
N. Meropol
Journal of Clinical Oncology
2008
Corpus ID: 207019406
PURPOSE As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE